INGN — Inogen, Inc.

Summary of Inogen's Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $92.4 million, up 4% year-over-year.
• Domestic B2B Revenue: Increased 6.6% to $24.9 million.
• International B2B Revenue: Increased 18.8% to $38.4 million.
• Direct-to-Consumer Sales: Decreased 17.9% to $15.8 million, reflecting a strategic shift to a leaner model.
• Rental Revenue: Decreased 4.4% to $13.3 million.
• Gross Margin: 44.7%, down 182 basis points year-over-year due to increased B2B sales.
• Operating Expenses: Decreased 1.4% year-over-year to $48.4 million.
• GAAP Net Loss: $5.3 million, improved from a loss of $6 million in the prior year.
• Adjusted EBITDA: Positive $2.3 million, marking the third consecutive quarter of profitability.
• Cash Position: $124.5 million in cash, cash equivalents, and marketable securities, with no debt.

2. Strategic Updates and Business Highlights:

• Top Line Growth: Achieved seventh consecutive quarter of mid-single-digit revenue growth, driven by increased market adoption of portable oxygen concentrators (POCs) and strong performance in both domestic and international B2B channels.
• International Expansion: Continued focus on expanding in high-opportunity global markets, particularly in Europe, with plans for future entry into China.
• Product Innovation: Successful launch of the Voxi 5 stationary oxygen concentrator, enhancing the product portfolio and expected to drive future B2B sales.
• Simeox Development: Limited market release in the U.S. and ongoing trials in Europe and China to support reimbursement efforts.

3. Forward Guidance and Outlook:

• Full Year Revenue Guidance: Reiterated at $354 million to $357 million, reflecting approximately 6% growth year-over-year.
• Adjusted EBITDA Guidance: Raised to approximately $2 million, up from breakeven expectations.
• Q4 Revenue Expectations: Projected to be between $87 million and $90 million, indicating about 10% growth compared to Q4 2024.

4. Bad News, Challenges, or Points of Concern:

• Decline in Direct-to-Consumer Sales: The DTC channel saw a significant decrease in revenue, which may impact overall growth if not stabilized.
• Rental Revenue Decline: Continued pressure on rental gross margins due to lower reimbursement rates and a high mix of private payers.
• Gross Margin Pressure: Overall gross margin declined due to the increasing proportion of B2B sales, which typically have lower margins.

5. Notable Q&A Insights:

• International B2B Growth: The 19% growth in international B2B was attributed to ongoing efforts to deepen relationships and expand market share rather than a single large tender.
• Voxi 5 Sales Timeline: Initial sales have begun, but significant revenue contributions are expected in 2026.
• Simeox Reimbursement Progress: Positive feedback from initial users and ongoing trials are encouraging, but specific timelines for reimbursement in the U.S. remain unclear.

Overall, Inogen reported solid progress in Q3 2025, with consistent revenue growth and improved profitability, while also navigating challenges in certain sales channels and gross margins. The company remains optimistic about its strategic initiatives and market opportunities moving forward.